# DESCRIPTION

## BACKGROUND

- describe Chlamydia trachomatis infection
- motivate need for vaccine

## SUMMARY

- summarize invention

## DETAILED DESCRIPTION

- introduce vaults and their structure
- describe vault composition and proteins
- outline embodiments of vault-like particles as carriers
- describe immunogenic peptides and vaccine compositions
- define protective immunity and immune responses
- outline methods of using vaults as carriers and for delivery
- describe targeting moieties and Fc binding domains
- outline methods for treating or preventing Chlamydia infection
- define terms
- describe MVP and vault-like particles
- describe method of using vaults as carrier molecules
- describe vault-like particles with modified MVP
- describe vault-like particles with modified MVP for immunogenic peptides
- describe vault-like particles with modified MVP for heavy metal binding
- describe vault-like particles with modified MVP for polynucleotide binding
- describe vault-like particles with modified MVP for sensors
- describe vault-like particles with modified VPARP
- describe vault-like particles
- modify MVP with immunogenic peptides
- add receptor-binding domains to MVP
- add substance-binding domains to MVP
- modify MVP with multiple sequences
- provide examples of modified MVP
- describe further embodiments of modified MVP
- define modified vault-like particles
- describe methods of preventing damage using vault-like particles
- describe methods of delivering substances using vault-like particles
- describe methods of making and using vault-like particles

## EXAMPLES

### Example 1

- prepare chlamydia-vault-like particles (CVLPs)
- test immunogenic properties of CVLPs

### Example 2

- immunize mice with CVLPs
- analyze immune response to CVLPs
- test protection against chlamydial infection
- analyze antibody response to CVLPs

### Example 3

- test incorporation of CVLPs by dendritic cells

### Example 4

- induce antibodies against peptides
- analyze antibody development and specificity
- describe novel vaccine platform and its advantages

